Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | PTAFR | P25105 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.57 |
| ▸ | FNTB | P49356 | 1/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313654 | 0.88 | OPRD1 (0.64) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| Cycliramine SCHEMBL2109915 | 0.81 | MEN1 (0.82) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| SCHEMBL8314573 | 0.80 | OPRD1 (0.58) | OPRD1KCNH2OPRM1OPRK1LMNA | |
| SCHEMBL10460871 | 0.79 | OPRD1 (0.65) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL30567989 | 0.77 | OPRD1 (0.56) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| SCHEMBL21381637 | 0.77 | OPRD1 (0.56) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| Bromide SCHEMBL10461679 | 0.76 | OPRD1 (0.61) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL8233166 | 0.76 | PTAFR (0.53) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| Cycliramine SCHEMBL634920 | 0.73 | MEN1 (1.00) | OPRD1KCNH2PTAFRMEN1KMT2A | |
| SCHEMBL12751010 | 0.72 | OPRD1 (0.48) | OPRD1KCNH2KMT2AFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318996-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6762186-B2 | USE TO TREAT ALLERGY, NASAL CONGESTION, INFLAMMATORY AND CENTRAL NERVOUS SYSTEM-RELATED DISEASES | SCHERING CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1318996-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-06-27 | — | — | US | disclosed |
| WO-2002044141-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
| US-5432175-A | Antiallergic, antiinflammatory agents | SCHERING CORPORATION (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0553191-A1 | PYRIDINE AND PYRIDINE N-OXIDE DERIVATIVES OF DIARYL METHYL PIPERIDINES OR PIPERAZINES, AND COMPOSITIONS AND METHODS OF USE THEREOF. | SCHERING CORP (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992006971-A1 | PYRIDINE AND PYRIDINE N-OXIDE DERIVATIVES OF DIARYL METHYL PIPERIDINES OR PIPERAZINES, AND COMPOSITIONS AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | OPRD1 316/4885KCNH2 252/4885PTAFR 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.